Molsidomine decreases hyperoxia-induced lung injury in neonatal rats

BackgroundThe study's objective is to evaluate if Molsidomine (MOL), an anti-oxidant, anti-inflammatory, and anti-apoptotic drug, is effective in treating hyperoxic lung injury (HLI).MethodsThe study consisted of four groups of neonatal rats characterized as the Control, Control+MOL, HLI, HLI + MOL groups. Near the end of the study, the lung tissue of the rats were evaluated with respect to apoptosis, histopathological damage, anti-oxidant and oxidant capacity as well as degree of inflammation.ResultsCompared to the HLI group, malondialdehyde and total oxidant status levels in lung tissue were notably reduced in the HLI + MOL group. Furthermore, mean superoxide dismutase, glutathione peroxidase, and glutathione activities/levels in lung tissue were significantly higher in the HLI + MOL group as compared to the HLI group. Tumor necrosis factor-alpha and interleukin-1 beta elevations associated with hyperoxia were significantly reduced following MOL treatment. Median histopathological damage and mean alveolar macrophage numbers were found to be higher in the HLI and HLI + MOL groups when compared to the Control and Control+MOL groups. Both values were increased in the HLI group when compared to the HLI + MOL group.ConclusionsOur research is the first to demonstrate that bronchopulmonary dysplasia may be prevented through the protective characteristics of MOL, an anti-inflammatory, anti-oxidant, and anti-apoptotic drug.ImpactMolsidomine prophylaxis significantly decreased the level of oxidative stress markers.Molsidomine administration restored the activities of antioxidant enzymes.Molsidomine prophylaxis significantly reduced the levels of inflammatory cytokines.Molsidomine may provide a new and promising therapy for BPD in the future.Molsidomine prophylaxis decreased lung damage and macrophage infiltration in the tissue.